ANI Pharmaceuticals Inc
NASDAQ:ANIP

Watchlist Manager
ANI Pharmaceuticals Inc Logo
ANI Pharmaceuticals Inc
NASDAQ:ANIP
Watchlist
Price: 67.61 USD -1.1% Market Closed
Market Cap: 1.5B USD

ANI Pharmaceuticals Inc
Investor Relations

ANI Pharmaceuticals Inc. operates at the heart of the pharmaceutical industry with a focused strategy that blends generics with niche high-value medications. Born in the realm of specialty pharmaceuticals, the company has crafted a business model that leverages both organic growth and strategic acquisitions. This dual approach helps the company to broaden its product offerings and maintain a robust pipeline. By targeting niche markets often overlooked by larger pharmaceutical giants, ANI maximizes its opportunities in areas with less competitive congestion. Central to its operations is the manufacturing and marketing of generic prescription products that are not only critically required but also pose less risk of commoditization due to their complexity, regulatory hurdles, or limited manufacturing capabilities.

Revenue generation for ANI is a sophisticated blend of manufacturing, marketing, and brand positioning. The company's infrastructure supports integrated product development, regulatory approval, and scalable manufacturing processes. This allows them to efficiently bring to market a diverse portfolio of more than a hundred products across therapeutic areas. Additionally, ANI taps into revenue streams by producing legacy branded drugs often acquired from larger players looking to offload non-core assets. These legacy products, while sometimes in smaller volumes, benefit from loyal prescriber bases and established market presence, providing a steady income for the company. In essence, ANI Pharmaceuticals thrives on navigating the intricacies of the pharmaceutical supply chain, seizing opportunities in underexplored niches and refocusing the potential of undervalued brands.

Show more
Loading

Earnings Calls

2024 Q4
Mar 11, 2025
Show Transcript
Previous
Next
Hesai Group Achieves Record Growth and Profitability in 2024, Strong Outlook for 2025
2024 Q4
Mar 11, 2025

Hesai Group reported record net revenues of RMB 2 billion (USD 285 million) in 2024, doubling unit shipments to over 500,000. December marked a milestone with 100,000 monthly shipments. The company achieved a non-GAAP net profit of RMB 14 million (USD 1.9 million), turning profitable for the first time. For 2025, Hesai targets revenues of RMB 3 billion to 3.5 billion, a 44% to 69% increase, with shipments expected between 1.2 million and 1.5 million units. A new cost-effective LiDAR model priced at $200 aims to accelerate market penetration, while robotics shipments are expected to reach nearly 200,000 units.

Show Full Analysis

Management

Mr. Nikhil Lalwani
President, CEO & Director
No Bio Available
Mr. Stephen P. Carey
Senior VP of Finance & CFO
No Bio Available
Mr. Chad Gassert
Senior Vice President of Corporate Development & Strategy
No Bio Available
Mr. Christopher K. Mutz
Senior VP & Head of Rare Disease
No Bio Available
Mr. Ori Gutwerg
Senior Vice President of Generics
No Bio Available
Mr. Muthusamy Shanmugam MS R.Ph.
Head of R&D, COO of Novitium Operations & Director
No Bio Available
Mr. James G. Marken
Senior Vice President of Operations
No Bio Available
Ms. Elizabeth Powell J.D.
Chief Compliance Officer & Head of Legal of Rare Disease
No Bio Available
Ms. Meredith W. Cook J.D.
Senior VP, General Counsel & Corporate Secretary
No Bio Available
Ms. Krista L. Davis
Senior VP & Chief Human Resources Officer
No Bio Available

Contacts

Address
MINNESOTA
Baudette
210 W Main St
Contacts